Trial Profile

Pre-operative Phase II Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI Trial)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Pharmacodynamics
Acronyms BELLINI

Most Recent Events

16 Sep 2024 Results published in the Media Release
16 Sep 2024 According to Natera, Inc media release , a new paper from the BELLINI trial, published in Nature Medicine.
28 Mar 2024 Planned End Date changed from 7 Jan 2027 to 1 Jan 2033.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com